Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats

First Page		Document Content
Date: 2010-01-04 11:40:27 Neuroimaging Molecular biology Signal transduction Rolipram Phosphodiesterase-4 inhibitor Neurotransmitters Positron emission tomography Protein kinase A Phosphodiesterase 4 Biology Medicine Biochemistry		Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats Add to Reading List Source URL: intramural.nimh.nih.gov Download Document from Source Website File Size: 164,39 KB Share Document on Facebook

	PDF Document DocID: 142Q9 - View Document
	ADCIRCA® (tadalafil) NAME OF THE MEDICINE ADCIRCA® (tadalafil). Chemically, tadalafil is pyrazino[1’, 2’:1, 6]pyrido[3, 4-b]indole-1, 4-dione, 6-(1, 3benzodioxol-5-yl)-2, 3, 6, 7, 12, 12a-hexahydro-2-methyl-, (6R, DocID: ZJNL - View Document
	Briefing Book - April 2010 DocID: Gi0Z - View Document
	Caffeine-Containing Botanicals in Dietary Supplements from 2 to 4 cups of coffee, another 11 had equivalents ranging from 4 to 6 cups of coffee, and 4 products provided an amount of caffeine ranging from 7 to 8 cups of c DocID: xJ0K - View Document
	Docket No. OON[removed]Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane rm[removed]Rockville DocID: x8W7 - View Document